3-(pyridin-2-ylamino)-2H-isoquinolin-1-one | 958769-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 3-(pyridin-2-ylamino)-2H-isoquinolin-1-one
• 英文别名: 3-(2-pyridylamino)isoquinolin-1(2H)-one；3-(2-Pyridylamino)isocarbostyril
• CAS: 958769-84-1
• 化学式: C₁₄H₁₁N₃O
• 分子量: 237.261
• InChiKey: HHZRFWPJLIXTAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(pyridin-2-ylamino)-2H-isoquinolin-1-one 、 4-甲氧基苯甲醛 在 三甲基氯硅烷 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 18-(4-Methoxyphenyl)-9,11,17-triazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,11,13,15-heptaen-8-one
  参考文献：
  名称：

  缩合异喹啉。37. *使用3-（芳基氨基）-和3-（杂芳基氨基）异喹啉-1（2H）-的杂环

  摘要：

  在Me3SiCl存在下或在乙酸中，3-NHR-异喹啉-1（2H）-一（R = Ar）与芳族醛的反应导致二苯并[b，f] [1，8]衍生物的形成萘啶-5（6H）-1和苯并[f]异喹啉[3,4-b] [1，8]萘啶-5,9（6H，7H）-二酮。在Me3SiCl存在下，R = Het的反应给出5H-吡啶基[1'，2'：1,2]嘧啶基[4,5-c]异喹啉-5-酮，苯并[f]异喹啉[3， 4-b] [1,8]萘啶-5,9 [6H，7H]-二酮和新杂环系统的衍生物5H-pyrazino [1'，2'：1,2] pyrimido [4,5-c ]异喹啉-5-酮，5H- [1,3]噻唑洛[3'，2'：1,2]嘧啶基-[4,5-c]异喹啉-5-酮，5-H-苯并[f]吡唑啉[3，4-b] [1，8]萘啶-5-酮和异喹啉[3，4-b]-[1，5]萘啶-5（6H）-酮。

  DOI：

  10.1007/s10593-011-0763-7
• 作为产物：
  描述：

  苯酞 以 氯苯 为溶剂， 反应 5.0h， 生成 3-(pyridin-2-ylamino)-2H-isoquinolin-1-one
  参考文献：
  名称：

  Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B

  摘要：

  The cell division cycle 25B dual specificity phosphatase (Cdc25B) regulates the normal progression of the mammalian cell cycle by dephosphorylating and activating cyclin-dependent kinase (Cdk) complexes, particularly in response to DNA damage. Elevated Cdc25B levels enable a bypass of normal cell cycle checkpoints, and the overexpression of Cdc25B has been linked to a variety of human cancers. Thus, Cdc25B is an attractive target for the development of anticancer therapeutics. Herein we describe the synthesis and biological evaluation of a series of non-quinoid inhibitors of Cdc25B containing the 3-aminoisoquinolin-1(2H)-one pharmacophore. In addition to several strategies that address specific substitution patterns on isoquinolines, we have applied a regioselective Pd-catalyzed cross-coupling methodology to synthesize a new lead structure, 6-(3-aminophenyl)-3-(phenylamino) isoquinolin-1(2H)-one (13), which proved to be a reversible, competitive Cdc25B inhibitor with a K-i of 1.9 mu M. Compound 13 prevented human cancer cell growth and blocked Cdc25B-mediated mitotic checkpoint bypass. Molecular docking studies support binding near the catalytic site. (C) 2015 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2015.01.043

文献信息

• 3-(Hetarylamino)- and 3-[(hetarylmethyl)amino]-isoquinolin-1(2H)-ones
  作者：L. M. Potikha、R. M. Gutsul、V. A. Kovtunenko、A. A. Tolmachev

  DOI：10.1007/s10593-010-0531-0

  日期：2010.8

  The reaction of 2-(cyanomethyl)benzoic acid with amines RNH(2) (R = Ar, Het, CH(2)Ar, CH(2)Het) leads to the formation of the corresponding 3-NHR-isoquinolin-1(2H)-ones. When R = CH(2)Ar and CH(2)Het, there is a side reaction involving hydrolysis of the hydrolytically-unstable intermediates, derivatives of 2-(2-amino-2-iminoethyl) benzoic acid, leading to 2-R-isoquinoline-1,3(2H,4H)-diones.
• Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B
  作者：Kara M. George Rosenker、William D. Paquette、Paul A. Johnston、Elizabeth R. Sharlow、Andreas Vogt、Ahmet Bakan、John S. Lazo、Peter Wipf

  DOI：10.1016/j.bmc.2015.01.043

  日期：2015.6

  The cell division cycle 25B dual specificity phosphatase (Cdc25B) regulates the normal progression of the mammalian cell cycle by dephosphorylating and activating cyclin-dependent kinase (Cdk) complexes, particularly in response to DNA damage. Elevated Cdc25B levels enable a bypass of normal cell cycle checkpoints, and the overexpression of Cdc25B has been linked to a variety of human cancers. Thus, Cdc25B is an attractive target for the development of anticancer therapeutics. Herein we describe the synthesis and biological evaluation of a series of non-quinoid inhibitors of Cdc25B containing the 3-aminoisoquinolin-1(2H)-one pharmacophore. In addition to several strategies that address specific substitution patterns on isoquinolines, we have applied a regioselective Pd-catalyzed cross-coupling methodology to synthesize a new lead structure, 6-(3-aminophenyl)-3-(phenylamino) isoquinolin-1(2H)-one (13), which proved to be a reversible, competitive Cdc25B inhibitor with a K-i of 1.9 mu M. Compound 13 prevented human cancer cell growth and blocked Cdc25B-mediated mitotic checkpoint bypass. Molecular docking studies support binding near the catalytic site. (C) 2015 Published by Elsevier Ltd.
• Condensed isoquinolines. 37.* Heterocyclization using 3-(arylamino)- and 3-(hetarylamino)isoquinolin-1(2H)-ones
  作者：L. M. Potikha、R. M. Gutsul、A. S. Plaskon、V. A. Kovtunenko、A. A. Tolmachev

  DOI：10.1007/s10593-011-0763-7

  日期：2011.6

  acid leads to the formation of derivatives of dibenzo[b,f][1, 8]naphthyridin-5(6H)- one and benzo[f]isoquino[3,4-b][1, 8]naphthyridine-5,9(6H,7H)-dione. The reaction for R = Het in the presence of Me3SiCl gives derivatives of 5H-pyrido[1',2':1,2]pyrimido[4,5-c]isoquinolin-5-one, benzo[f]isoquinoline[3,4-b][1,8]naphthyridine-5,9[6H,7H]-dione, and derivatives of new heterocyclic systems, 5H-pyrazino[1'

  在Me3SiCl存在下或在乙酸中，3-NHR-异喹啉-1（2H）-一（R = Ar）与芳族醛的反应导致二苯并[b，f] [1，8]衍生物的形成萘啶-5（6H）-1和苯并[f]异喹啉[3,4-b] [1，8]萘啶-5,9（6H，7H）-二酮。在Me3SiCl存在下，R = Het的反应给出5H-吡啶基[1'，2'：1,2]嘧啶基[4,5-c]异喹啉-5-酮，苯并[f]异喹啉[3， 4-b] [1,8]萘啶-5,9 [6H，7H]-二酮和新杂环系统的衍生物5H-pyrazino [1'，2'：1,2] pyrimido [4,5-c ]异喹啉-5-酮，5H- [1,3]噻唑洛[3'，2'：1,2]嘧啶基-[4,5-c]异喹啉-5-酮，5-H-苯并[f]吡唑啉[3，4-b] [1，8]萘啶-5-酮和异喹啉[3，4-b]-[1，5]萘啶-5（6H）-酮。